Melanotan II is among the most misunderstood compounds in this field, partly because it is routinely confused with a differently named and differently regulated molecule. This article separates the two and sets out the current position.
Melanotan II is a synthetic cyclic lactam analogue of α-melanocyte stimulating hormone. The cyclisation — a ring formed within the peptide structure — gives it considerably greater resistance to enzymatic degradation than the linear native hormone.
That stability is a practical property. A molecule that survives long enough to be worked with reliably is more useful as a laboratory reference material than one that degrades during an assay.
It originates from academic research into melanocortin receptor pharmacology rather than from a commercial development programme.
Melanocortin receptors come in several subtypes, conventionally MC1R through MC5R, with different tissue distributions and associated functions.
Melanotan II acts across several of these rather than selectively at one. In most therapeutic contexts non-selectivity is a drawback. In receptor pharmacology research it is the opposite: a non-selective agonist is exactly what you want as a comparator when characterising how selective a newer analogue is.
This is the basis on which MT2 appears in the research literature — as a reference ligand in profiling work.
These two are persistently confused, including in otherwise careful sources, and the distinction is important.
Afamelanotide is a selective melanocortin analogue that holds a marketing authorisation for a specific rare indication, administered under medical supervision. Melanotan II is a different molecule, non-selective, and unlicensed.
A licensed status attaching to one does not transfer to the other. Any source treating them as interchangeable is unreliable on this topic generally.
Melanotan II is not a licensed medicine in the United Kingdom. No product containing it holds a marketing authorisation from the MHRA.
The MHRA has issued public warnings about unlicensed products containing melanotan and has taken enforcement action against their sale. That position is a matter of public record and is linked in the references.
Material supplied for research is supplied for in-vitro laboratory use only, and not for administration to humans or animals.
Where a supplier cannot state a confirmed strength and composition for a product, that should be said plainly rather than filled in with an assumed figure.
Our MT2 listing does not publish a strength, because one has not been confirmed. It will be published when it is confirmed and not before. We would rather carry an incomplete listing than a wrong one.
This article is reference material describing published research. It is not medical advice, not a therapeutic claim, and contains no dosing or administration guidance.